A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

NCT04576208 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business Decision (no safety or efficacy concerns)

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: TAK-788
DRUG: Antidiarrheal prophylaxis

Sponsor

Takeda